Biocon has signed a license agreement with Janssen Sciences Ireland clearing the way for the commercialisation of Yesintek, its proposed biosimilar to Stelara (Ustekinumab), in Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea and Kazakhstan with immediate effect.

This milestone builds on the company’s previously announced agreements with Janssen that secured market entry dates for Yesintek in the US, and in Europe, the UK, Canada and Japan.

These additional market entry rights for biosimilar Ustekinumab will allow Biocon to offer an affordable and effective treatment option for patients impacted by autoimmune diseases in these markets.

Yesintek is a human interleukin-12 and -23 antagonist that disrupts IL-12 and IL-23 mediated signaling in immune mediated diseases and has been approved for the treatment of Crohn’s Disease (CD), Ulcerative Colitis (UC), plaque psoriasis and psoriatic arthritis.

The reference brand, Stelara, had worldwide sales of USD 6.08 billion in 2025.